Steve Schonfeld’s Sonnet BioTherapeutics SONN Stock Holding History

Steve Schonfeld’s Portfolio SONN Stock Details SONN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-5	Closed	-$31K	–	1856
2020 Q3	$31K	Buy	+5	New	+$36K	﹤0.01%	1313

Other funds holding SONN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $8.83B AUM 38.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

MSFS

Main Street Financial Solutions Newtown, Pennsylvania $1.56B AUM 24.84% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Steve Schonfeld's SONN Position: Q4 2020 in Review

Steve Schonfeld sold out of Sonnet BioTherapeutics (SONN) in Q4 2020, closing a stake of 5 shares — an estimated $31K sold.

Steve Schonfeld first reported a position in SONN in Q3 2020 and held it in 1 quarter. The position peaked at $31K in Q3 2020. 8 funds tracked by Wall St. Rank hold SONN as of Q4 2020.

Steve Schonfeld reported no remaining Sonnet BioTherapeutics position as of Q4 2020 after selling out during the quarter.
Steve Schonfeld sold 5 Sonnet BioTherapeutics shares in Q4 2020, an estimated $31K.
Steve Schonfeld first reported a position in Sonnet BioTherapeutics in Q3 2020 and held it in 1 quarter.
Steve Schonfeld's Sonnet BioTherapeutics position peaked at $31K in Q3 2020.
8 funds tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q4 2020.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.